Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42

被引:30
作者
Moran, E
Cleary, I
Larkin, AM
Amhlaoibh, RN
Masterson, A
Scheper, RJ
Izquierdo, MA
Center, M
OSullivan, F
Clynes, M
机构
[1] FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,AMSTERDAM,NETHERLANDS
[2] CATALAN INST ONCOL,DEPT ONCOL,BARCELONA,SPAIN
[3] KANSAS STATE UNIV,DIV BIOL,MANHATTAN,KS 66506
关键词
P-170; LRP; MRP; topoisomerase II alpha; GST pi; vimentin; cytokeratin; doxorubicin;
D O I
10.1016/S0959-8049(96)00501-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Variants of the human ovarian carcinoma cell line, OAW42, exhibiting low-level intrinsic resistance (OAW42-SR) and drug-induced higher-level resistance (OAW42-A1 & OAW42-A), were studied along with a sensitive clonal population (OAW42-S) which was isolated from OAW42-SR. Expression of the MDR-associated protein P-170, the more recently discovered LRP (lung resistance-related protein) and MRP (multidrug resistance-associated protein), topoisomerase II alpha and beta, GST pi and the cytoskeletal proteins, cytokeratin 8 and vimentin, were studied (using immunocytochemistry and Western blotting techniques) in conjunction with drug (doxorubicin) accumulation and subcellular distribution. Expression of mRNA for P-170, MRP, topoisomerase 11 alpha and beta and GST pi was studied using RT-PCR (reverse transcriptase polymerase chain reaction). Results indicate differential co-expression of four MDR-associated parameters (P-170, MRP, LRP and reduced topoisomerase II alpha and beta) in the OAW42-SR and OAW42-A1 variants, whereas resistance in the OAW42-A variant appeared to be mainly P-170 mediated. Comparable amounts of MRP and greater amounts of LRP were detected in the OAW42-S cells compared to the OAW42-SR variant (which showed increased resistance compared to the OAW42-S cells), but all cell lines expressed similar low-level amounts of MRP mRNA (by RT-PCR). GST pi levels did not differ markedly between variants. Increased levels of the cytoskeletal proteins were observed with increasing levels of resistance. The relative resistance of the variants, OAW42-SR and OAW42-A1, compared with OAW42-S was seen to change during increased serial passaging of the cells. There was greater drug accumulation by the sensitive OAW42-S cell line compared with that of the resistant variants, particularly the most highly resistant OAW42-A cells. Both verapamil and cyclosporin A effectively restored the accumulation defects seen in the resistant variants, cyclosporin A being the more effective of the two. Subcellular location of drug was predominantly in the nucleus with maximum levels seen in the sensitive OAW42-S variant and minimum levels in the most resistant OAW42-A clone. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:652 / 660
页数:9
相关论文
共 30 条
  • [1] AUSUBEL MF, 1991, CURRENT PROTOCOLS MO
  • [2] RELATION BETWEEN OVARIAN CARCINOMA-ASSOCIATED ANTIGENS IN TUMOR-TISSUE AND DETACHED CYST FLUID CELLS OF PATIENTS WITH OVARIAN NEOPLASMS
    BAR, JK
    HARLOZINSKA, A
    SOBANSKA, E
    CISLO, M
    [J]. TUMORI, 1994, 80 (01) : 50 - 55
  • [3] CYTOFLUORESCENCE LOCALIZATION OF ADRIAMYCIN IN RESISTANT COLON CANCER-CELLS
    CHAUFFERT, B
    MARTIN, F
    CAIGNARD, A
    JEANNIN, JF
    LECLERC, A
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1984, 13 (01) : 14 - 18
  • [4] CLYNES M, 1993, IN VITRO CELL DEV-AN, V29A, P171
  • [5] DIFFERENT VIMENTIN EXPRESSION IN 2 CLONES DERIVED FROM A HUMAN COLOCARCINOMA CELL-LINE (LOVO) SHOWING DIFFERENT SENSITIVITY TO DOXORUBICIN
    CONFORTI, G
    CODEGONI, AM
    SCANZIANI, E
    DOLFINI, E
    DASDIA, T
    CALZA, M
    CANIATTI, M
    BROGGINI, M
    [J]. BRITISH JOURNAL OF CANCER, 1995, 71 (03) : 505 - 511
  • [6] FRICHE E, 1991, CANCER RES, V51, P4213
  • [7] GANAPATHI R, 1983, CANCER RES, V45, P3696
  • [8] P-GLYCOPROTEIN IN HUMAN SARCOMA - EVIDENCE FOR MULTIDRUG RESISTANCE
    GERLACH, JH
    BELL, DR
    KARAKOUSIS, C
    SLOCUM, HK
    KARTNER, N
    RUSTUM, YM
    LING, V
    BAKER, RM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) : 1452 - 1460
  • [9] GRANT CE, 1994, CANCER RES, V54, P357
  • [10] TOPOISOMERASE-II IN MULTIPLE-DRUG RESISTANCE
    HOFMANN, GA
    MATTERN, MR
    [J]. CYTOTECHNOLOGY, 1993, 12 (1-3) : 137 - 154